Clinical trial
Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
NCT00358319 · H. Lee Moffitt Cancer Center and Research Institute, Other · Terminated
Key facts
| NCT number | NCT00358319 |
|---|---|
| Title | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma |
| Official title | Phase I/II Trial of Valproic Acid and Karenitecin for Metastatic Malignant Melanoma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | BioNumerik Pharmaceuticals, Inc. Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | Karenitecin, Valproic Acid |
| Enrollment | 42 |
| Start date | Mar 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Jul 31, 2006 |
| Last update posted | Nov 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: